Healthcare stocks, particularly in gene-editing and obesity, are presenting compelling investment opportunities despite being overlooked due to rising interest rates and AI sector hype. Crispr Therapeutics and Vertex Pharmaceuticals are demonstrating commercial traction with Casgevy, their gene-editing treatment for blood disorders, reporting $30 million in Q2 2025 sales and anticipating further growth. Intellia Therapeutics is nearing pivotal readouts in 2026 for its CRISPR programs, potentially introducing the first single-dose in vivo gene therapy. Additionally, Recursion Pharmaceuticals, utilizing an AI-powered drug discovery platform, has critical clinical trial updates expected in late 2025, while Viking Therapeutics is advancing its dual GLP-1/GIP agonist for the lucrative obesity market, with key data points and strategic adjustments for its oral formulation. These companies are approaching significant catalysts that could re-rate their valuations.
The healthcare sector, particularly biotech and drug development, has experienced capital outflows and valuation compression since 2022 due to rising interest rates, despite significant pipeline advancements. This market dynamic has created an opportunity in several innovative companies now trading at a fraction of previous highs, contrasting with the high multiples seen in the AI sector. The overall sentiment for these specific opportunities is strongly positive and bullish. Crispr Therapeutics (CRSP) and Vertex Pharmaceuticals (VRTX) are demonstrating commercial traction with Casgevy, their gene-editing treatment for sickle cell disease, reporting $30 million in Q2 2025 sales and anticipating continued growth through 2026 as more of the 75 cleared centers administer the treatment. Crispr also holds fully-owned pipeline assets like CTX112, with potential stock catalysts from late 2025 data readouts. Intellia Therapeutics (NTLA) is nearing pivotal clinical milestones, with topline Phase 3 results for lonvoguran ziclomeran (NTLA-2002) expected in H1 2026 and a pivotal trial underway for nex-z (NTLA-2001), which showed a 91% TTR protein reduction. Successful outcomes could position Intellia as a leader in single-dose in vivo CRISPR therapy, potentially resetting gene-editing valuations. Recursion Pharmaceuticals (RXRX), leveraging an AI-powered discovery platform with significant pharma backing, anticipates critical clinical trial updates in late 2025 that could re-rate its individual programs. Viking Therapeutics (VKTX) is advancing its dual GLP-1/GIP agonist, VK2735, for obesity, with the injectable version demonstrating up to 14.7% weight loss in mid-stage studies. While the oral formulation faced dropout issues due to rapid dose escalation, this was attributed to administration, not the compound, suggesting improved tolerability with a slower titration schedule could unlock significant potential in the projected $100 billion obesity market.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
